But there will be some costs that we’ll efficient on, even though we’re going to eliminate separate offices, separate audits. And then there’s probably some people savings in there.
But the real benefit that we’ve always said is putting the two together, and being able to cross-sell between the two. We’ve been trying to do that and had some success on the international front so far. We’ve had some modest success so far in the U.S. But by integrating the two companies and really being one platform, one company, one salesforce, we’re starting to see the early signs of the opportunity sets in different basics that Spartan operates in today, start to come through from the CCLP salesforce. That’ll accelerate now. We can just operate as one head of sales, one sales division, and really understand the products that are available to sell.
So I think you’ll see in 2022, more opportunities for the products of Spartan to be across multiple basins. Right now, Spartan operates generally, as you can see from the information we provide on our website, generally south Texas and north Louisiana. But we have a smattering of assets scattered in a couple of other basins.
I think we can penetrate those a lot more with a lot more assets deployed there, because we just didn’t have salesforces over there. On the Spartan side, CSI does have salespeople there. So I think it’s a revenue and EBITDA-generating opportunity set versus the cost side, but we’re going to get some of both.
Brian DiRubbio: Got it. And then I know it’s probably early, but how should we start thinking about combined CapEx? And do you have any thoughts on what 2022, CapEx could be in 2022?
John Jackson: We haven’t gotten our Board through our 2022 budget yet and capital spending. And really, it was somewhat predicated on this transaction happening. These series of transactions were if Spartan combined with CSI and is it not. But I think on the — if you look at — what I can tell you is on the Spartan side, the CapEx for next year will not be extensive at the moment.
We have a number of opportunities that have popped up recently that could be pretty exciting, but right now, they wouldn’t be in our core capital budget. If they pop up and actually happen, so there’ll be a contracted business, we’d add that to the equation. But right now, we have, I think, some idle equipment on the Spartan side, just like we do on the CCLP side, that doesn’t require as much, if any, make-ready, very nominal make-ready.
Our maintenance capital on the Spartan side is less than $0.5 million a year. So from a CapEx on the Spartan acquisition, it’s probably going to be $2 million to $4 million or $5 million at most of additives, unless we have a significant project. And we have 2 or 3 of those percolating.
So I’m rambling around a lot here, but the reality is core business, it’s less than $5 million probably on an ongoing CapEx spend basis, except for one-off projects that come up.
Brian DiRubbio: Got it. That’s at least helpful. And then just — and the reason I ask you that is I’m trying to get a sense of how you’re going to prioritize capital allocation going forward. You’re reducing modestly some of your interest expense, you obviously had an EBITDA from Spartan. Is the thought process though that 2022 is going to be a refreshment grow year, or are you still looking to maximize cash generation in the combined entity?